

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [Agra Ventures Ltd. \(formerly AgraFlora Organics International Inc.\) \(the "Issuer" or the "Company" or "AgraFlora"\)](#).

Trading Symbol: [AGRA](#)

Number of Outstanding Listed Securities: [13,388,503 as at November 30, 2021](#)

Date: [December 6, 2021](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer confirms that the impact of COVID-19 on its business and operations has been minimal. The Issuer is continuing to move forward with obtaining its license to cultivate cannabis from Health Canada and is continuing with building](#)

out the Issuer's 2.2 million square foot Delta Greenhouse Facility (the "Delta Facility")

2. Provide a general overview and discussion of the activities of management.

During the month of **November 2021**, the Issuer:

- Announced that its wholly owned subsidiary, Propagation Services Canada Inc. has signed a Cannabis Purchase Agreement with an arm's length third party.
 - Announced that its wholly owned subsidiary, Farmako GmbH, has conducted the first commercial import of cannabis extracts from Poland to Germany.
 - Announced the approval of issuing 8,744 common shares at a deemed price of \$0.84 per share as payment of the portion of the quarterly amount of interest due in shares on a loan entered into in December 2020.
 - Tended to general management and administrative matters.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

On **November 18, 2021**, the Issuer announced that its wholly owned subsidiary, Farmako GmbH ("**Farmako**"), has conducted the first commercial import of cannabis extracts from Poland to Germany, which is the largest medical cannabis market in Europe. The extracts have been produced according to the highest standards by Pharmacann Polska Sp. z o.o., an EU GMP-certified cannabis company and part of PHCANN International ("**PHCANN International**" or the "**Collaborator**").

Launched under Farmako's brand, the extracts are produced by PHCANN International's subsidiaries from selected hybrid cannabis flowers grown under GACP – EU GMP indoor conditions. The cannabis is grown completely without the use of pesticides and is extracted according to highest industry standards under strict quality control at the EU GMP facility. With the launch of the extracts, Farmako strengthens its position as supplier with a comprehensive portfolio in the medical cannabis market – from flowers, extracts and isolate to testkits for pharmacies.

The overall German medical cannabis market is currently characterized by a considerable number of wholesalers and manufacturers that offer all kinds of flower products – often the same products under different names – which can be confusing for doctors and patients. Extracts offer a solution with their standardized cannabinoid concentrations and enable a controlled and constant medication for patients. Still, the medical cannabis extracts market is small and its growth has

been impeded by high prices, which historically has discouraged patients, doctors and insurance companies from using them. Farmako wants to change this by providing its products at affordable prices to further establish extracts as acknowledged cannabis medication.

Separately, Farmako has recently signed a large wholesale contract for its THC testkits with a cannabis producer that will offer the testkits together with their own cannabis products. This arrangement further emphasizes Farmako's position as reliable industry partner.

More details on Farmako's products can be found in the section for medical staff on Farmako's website at www.farmako.de/en/.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable for the month of **November 2021**.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On **November 15, 2021**, the Issuer announced that its wholly owned subsidiary, Propagation Services Canada Inc. d.b.a. Boundary Bay Cannabis ("**Boundary Bay Cannabis**"), has signed a Cannabis Purchase Agreement (the "**Offtake Agreement**" or "**Contract**") with an arm's length third party (the "**Purchaser**"). The Offtake Agreement specifies the recurring monthly purchase of a defined minimum quantity of cannabis in dried flower form, with a minimum range of THC content, terpenes and other specifications. Due to the confidentiality clause within the Offtake Agreement, no specific price, volume or other such information can be disclosed by either the Company and its affiliates or by the Purchaser.

Subject to other terms and conditions, the Contract has an initial term of six months, with a renewal term of equal length if not terminated by either party, and a delivery date of the first order of cannabis being on or before November 23, 2021. Entering into the Offtake Agreement marks a significant milestone for the Company as it formalizes the ongoing sale of Boundary Bay Cannabis products grown at the Delta greenhouse complex on a wholesale basis for the first time. Importantly, it establishes a new relationship with the Purchaser, which was originally brokered by a separate third party (the "**Broker**") on the Company's behalf. In exchange for establishing the relationship between Boundary Bay Cannabis to the Purchaser, the Company has agreed to pay the Broker an average rate of 4.9 per cent on all sales over the term of the Contract from Boundary Bay Cannabis to the Purchaser.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable for the month of **November 2021**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable for the month of **November 2021**.

8. Describe the acquisition of new customers or loss of customers.

Not applicable for the month of **November 2021**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable for the month of **November 2021**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable for the month of **November 2021**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable for the month of **November 2021**.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable for the month of **November 2021**.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On **November 21, 2021**, the Issuer announced that its Board of Directors has approved the payment of the portion of the quarterly amount of interest due in common shares for a loan entered in December 2020. Pursuant to the payment of

the interest, the Company issued an aggregate amount of 8,744 common shares at a deemed price of \$0.84 per share. All securities issued will be subject to a hold period of four months and one day from the date of issuance.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	8,744	Issued pursuant to a settlement of debt ⁽¹⁾	N/A

Notes:

(1) On November 21, 2021, the Issuer announced that its Board of Directors has approved the payment of the portion of the quarterly amount of interest due in common shares for a loan entered in December 2020. Pursuant to the payment of the interest, the Company issued an aggregate amount of 8,744 common shares at a deemed price of \$0.84 per share. All securities issued will be subject to a hold period of four months and one day from the date of issuance.

15. Provide details of any loans to or by Related Persons.

Not applicable for the month of **November 2021**.

16. Provide details of any changes in directors, officers or committee members.

Not applicable for the month of **November 2021**.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis dated November 29, 2021 for the period ended September 30, 2021 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at www.sedar.com and on the Issuer's disclosure hall with the CSE at www.thecse.com.

Additional trends that are likely to impact the Issuer include:

COVID-19

The outbreak of the coronavirus ("COVID-19") pandemic has impacted the Issuer's plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the

Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that be brought about by the COVID-19 pandemic on global financial markets reduce resource prices, share prices and financial liquidity and thereby that severely limit the financing capital available.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 6, 2021

Elise Coppens
Name of Director or Senior
Officer

"Elise Coppens"
Signature

CEO & Director
Official Capacity

Issuer Details Name of Issuer <u>Agra Ventures Ltd.</u>	For Month End <u>November 2021</u>	Date of Report YY/MM/D <u>21/12/06</u>
Issuer Address <u>Suite 810 - 789 West Pender Street</u>		
City/Province/Postal Code <u>Vancouver, British Columbia, V6C 1H2</u>	Issuer Fax No. <u>604-687-3141</u>	Issuer Telephone No. <u>604-687-2038</u>
Contact Name <u>Elise Coppens</u>	Contact Position <u>CEO & Director</u>	Contact Telephone No. <u>604-687-2038</u>